InflaRx (NASDAQ:IFRX - Get Free Report) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 248,900 shares, a growth of 15.0% from the December 15th total of 216,500 shares. Based on an average daily trading volume, of 264,900 shares, the short-interest ratio is currently 0.9 days.
InflaRx Price Performance
Shares of IFRX traded down $0.01 during trading hours on Monday, hitting $2.54. 178,129 shares of the stock were exchanged, compared to its average volume of 193,527. The firm has a market capitalization of $149.56 million, a P/E ratio of -2.35 and a beta of 1.66. InflaRx has a fifty-two week low of $1.16 and a fifty-two week high of $2.82. The business has a 50-day moving average of $2.32 and a 200-day moving average of $1.80.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a "buy" rating and issued a $8.00 target price on shares of InflaRx in a report on Thursday.
View Our Latest Analysis on IFRX
About InflaRx
(
Get Free Report)
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.
Further Reading
Before you consider InflaRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InflaRx wasn't on the list.
While InflaRx currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
